<DOC>
	<DOCNO>NCT01501760</DOCNO>
	<brief_summary>Corneal newvessels may arise fan pathology , induce long-standing corneal opacification require keratoplasty . These last year , VEGF inhibitor design reduce newascularization induce gastric cancer age-related macular degeneration . A report publish show interest VEGF inhibitor treat corneal newvessels , randomize study achieve date . This study design assess efficacy Bevacizumab , VEGF inhibitor monoclonal antibody , reduce surface corneal newvessels compare placebo</brief_summary>
	<brief_title>Efficacy Safety Study Avastin Treat Neovascularisation Cornea</brief_title>
	<detailed_description>This study involve 42 outpatient CHU Limoges , Bordeaux , Toulouse , address corneal pathology include corneal newvessels . The patient randomly assign two group , one receiving three subconjunctival injection bevacizumab , three subconjunctival injection placebo ( Balanced salt solution ) . The progression newvessels assess use color photograph picture-analyser software calculate percentage corneal surface occupy newvessels . Randomization , preparation study drug placebo syrinx perform central pharmacy CHU de Limoges . Patients followed-up outpatient , visit schedule 15 day treatment , baseline , 1 month , 2 month , 3 month , 6 month . - Primary outcome : To demonstrate Bevacizumab subconjunctival injection effectiveness corneal neovascularisation reduction definite superior percentage patient reduction high 30 % corneal surface occupy newvessels , 3 month , group Bevacizumab compare group placebo - Secondary outcome : - The effectiveness bevacizumab reduce percentage corneal surface occupy neovascularization 6 month - The effectiveness bevacizumab reduce use corneal graft . - The local general toxicity bevacizumab administer subconjunctival way .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>inclusion criterion : Patients corneal neovascularization whatever origin Patient receive treatment topical corticosteroid month precede inclusion . Patient properly inform signed consent Patient age 18 Patient affiliate health insurance plan benefit regime Patients receive local general treatment concomitant prostaglandin derivative Patients current infection cornea tissue / organ Women childbearing age without contraception Pregnancy Lactation Patient participate another study Patient contact lenses Patients uncontrolled hypertension Patient history stroke , myocardial infarction , angina pectoris , thrombophlebitis , Raynaud 's phenomenon . Patients hypersensitive active substance excipients Patients hypersensitive product Chinese hamster ovary cell recombinant human humanize antibody . Patients active bacterial eye infection , fungal , parasitic viral infection ( exception herpes )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>